Cargando…

The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients

BACKGROUND: The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn). METHODS: A retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruge, Max, Gomez, Joanne Michelle D., du Fay de Lavallaz, Jeanne, Hlepas, Alexander, Rahman, Annas, Patel, Priya, Lavani, Prutha, Nair, Gatha G., Jahan, Nusrat, Simmons, J. Alan, Rao, Anupama K, Williams, Kim A., Volgman, Annabelle Santos, Marinescu, Karolina, Suboc, Tisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330143/
https://www.ncbi.nlm.nih.gov/pubmed/34358679
http://dx.doi.org/10.1016/j.carpath.2021.107374
_version_ 1783732640604487680
author Ruge, Max
Gomez, Joanne Michelle D.
du Fay de Lavallaz, Jeanne
Hlepas, Alexander
Rahman, Annas
Patel, Priya
Lavani, Prutha
Nair, Gatha G.
Jahan, Nusrat
Simmons, J. Alan
Rao, Anupama K
Williams, Kim A.
Volgman, Annabelle Santos
Marinescu, Karolina
Suboc, Tisha
author_facet Ruge, Max
Gomez, Joanne Michelle D.
du Fay de Lavallaz, Jeanne
Hlepas, Alexander
Rahman, Annas
Patel, Priya
Lavani, Prutha
Nair, Gatha G.
Jahan, Nusrat
Simmons, J. Alan
Rao, Anupama K
Williams, Kim A.
Volgman, Annabelle Santos
Marinescu, Karolina
Suboc, Tisha
author_sort Ruge, Max
collection PubMed
description BACKGROUND: The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn). METHODS: A retrospective study of 1331 adult patients with COVID-19 admitted to the Rush University System in Illinois, USA was performed. Patients without cTn measurement during their admission or a history of end stage renal disease or stage 5 chronic kidney disease were excluded. Using logistic regression adjusted for baseline characteristics, pre-existing comorbidities, and other laboratory markers of inflammation, cTn was assessed as a predictor of 60-day mortality and severe COVID-19 infection, consisting of a composite of 60-day mortality, need for intensive care unit, or requiring non-invasive positive pressure ventilation or intubation. RESULTS: A total of 772 patients met inclusion criteria. Of these, 69 (8.9%) had mild cTn elevation (> 1 to < 2x upper limit of normal (ULN)) and 46 (6.0%) had severe cTn elevation (≥ 2x ULN). Regardless of baseline characteristics, comorbidities, and initial c-reactive protein, lactate dehydrogenase, and ferritin, when compared to the normal cTn group, mild cTn elevation and severe cTn elevation were predictors of severe COVID-19 infection (adjusted OR [aOR] aOR 3.00 [CI: 1.51 – 6.29], P < 0.01; aOR 9.96 [CI: 2.75 – 64.23], P < 0.01, respectively); severe cTn elevation was a predictor of in-hospital mortality (aOR 2.42 [CI: 1.10 – 5.21], P < 0.05) and 60-day mortality (aOR 2.45 [CI: 1.13 – 5.25], P < 0.05). CONCLUSION: In our cohort, both mild and severe initial cTn elevation were predictors of severe COVID-19 infection, while only severe cTn elevation was predictive of 60-day mortality. First cTn value on hospitalization is a valuable longitudinal prognosticator for COVID-19 disease severity and mortality.
format Online
Article
Text
id pubmed-8330143
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-83301432021-08-03 The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients Ruge, Max Gomez, Joanne Michelle D. du Fay de Lavallaz, Jeanne Hlepas, Alexander Rahman, Annas Patel, Priya Lavani, Prutha Nair, Gatha G. Jahan, Nusrat Simmons, J. Alan Rao, Anupama K Williams, Kim A. Volgman, Annabelle Santos Marinescu, Karolina Suboc, Tisha Cardiovasc Pathol Original Article BACKGROUND: The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn). METHODS: A retrospective study of 1331 adult patients with COVID-19 admitted to the Rush University System in Illinois, USA was performed. Patients without cTn measurement during their admission or a history of end stage renal disease or stage 5 chronic kidney disease were excluded. Using logistic regression adjusted for baseline characteristics, pre-existing comorbidities, and other laboratory markers of inflammation, cTn was assessed as a predictor of 60-day mortality and severe COVID-19 infection, consisting of a composite of 60-day mortality, need for intensive care unit, or requiring non-invasive positive pressure ventilation or intubation. RESULTS: A total of 772 patients met inclusion criteria. Of these, 69 (8.9%) had mild cTn elevation (> 1 to < 2x upper limit of normal (ULN)) and 46 (6.0%) had severe cTn elevation (≥ 2x ULN). Regardless of baseline characteristics, comorbidities, and initial c-reactive protein, lactate dehydrogenase, and ferritin, when compared to the normal cTn group, mild cTn elevation and severe cTn elevation were predictors of severe COVID-19 infection (adjusted OR [aOR] aOR 3.00 [CI: 1.51 – 6.29], P < 0.01; aOR 9.96 [CI: 2.75 – 64.23], P < 0.01, respectively); severe cTn elevation was a predictor of in-hospital mortality (aOR 2.42 [CI: 1.10 – 5.21], P < 0.05) and 60-day mortality (aOR 2.45 [CI: 1.13 – 5.25], P < 0.05). CONCLUSION: In our cohort, both mild and severe initial cTn elevation were predictors of severe COVID-19 infection, while only severe cTn elevation was predictive of 60-day mortality. First cTn value on hospitalization is a valuable longitudinal prognosticator for COVID-19 disease severity and mortality. Elsevier Inc. 2021 2021-08-03 /pmc/articles/PMC8330143/ /pubmed/34358679 http://dx.doi.org/10.1016/j.carpath.2021.107374 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Ruge, Max
Gomez, Joanne Michelle D.
du Fay de Lavallaz, Jeanne
Hlepas, Alexander
Rahman, Annas
Patel, Priya
Lavani, Prutha
Nair, Gatha G.
Jahan, Nusrat
Simmons, J. Alan
Rao, Anupama K
Williams, Kim A.
Volgman, Annabelle Santos
Marinescu, Karolina
Suboc, Tisha
The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
title The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
title_full The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
title_fullStr The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
title_full_unstemmed The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
title_short The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
title_sort prognostic value of cardiac troponin for 60 day mortality and major adverse events in covid-19 patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330143/
https://www.ncbi.nlm.nih.gov/pubmed/34358679
http://dx.doi.org/10.1016/j.carpath.2021.107374
work_keys_str_mv AT rugemax theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT gomezjoannemichelled theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT dufaydelavallazjeanne theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT hlepasalexander theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT rahmanannas theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT patelpriya theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT lavaniprutha theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT nairgathag theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT jahannusrat theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT simmonsjalan theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT raoanupamak theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT williamskima theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT volgmanannabellesantos theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT marinescukarolina theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT suboctisha theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT rugemax prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT gomezjoannemichelled prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT dufaydelavallazjeanne prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT hlepasalexander prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT rahmanannas prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT patelpriya prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT lavaniprutha prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT nairgathag prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT jahannusrat prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT simmonsjalan prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT raoanupamak prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT williamskima prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT volgmanannabellesantos prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT marinescukarolina prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients
AT suboctisha prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients